Patrick Rossignol
Patrick Rossignol
Nancy Clinical Investigation Centre, Inserm 1433, CHRU Nancy,Université de Lorraine, INI-CRCT FCRIN
Geverifieerd e-mailadres voor chru-nancy.fr - Homepage
Geciteerd door
Geciteerd door
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ...
Science 370 (6515), eabd4585, 2020
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Q Zhang, P Bastard, Z Liu
Science 370 (6515), 2020
The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology
W Mullens, K Damman, VP Harjola, A Mebazaa, HP Brunner‐La Rocca, ...
European journal of heart failure 21 (2), 137-155, 2019
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
A Ortiz, A Covic, D Fliser, D Fouque, D Goldsmith, M Kanbay, F Mallamaci, ...
The lancet 383 (9931), 1831-1843, 2014
Galectin-3 mediates aldosterone-induced vascular fibrosis
L Calvier, M Miana, P Reboul, V Cachofeiro, E Martinez-Martinez, ...
Arteriosclerosis, thrombosis, and vascular biology 33 (1), 67-75, 2013
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms
V Fontaine, MP Jacob, X Houard, P Rossignol, D Plissonnier, ...
The American journal of pathology 161 (5), 1701-1710, 2002
The systemic nature of CKD
C Zoccali, R Vanholder, ZA Massy, A Ortiz, P Sarafidis, FW Dekker, ...
Nature Reviews Nephrology 13 (6), 344-358, 2017
Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints
A Kearney-Schwartz, P Rossignol, S Bracard, J Felblinger, R Fay, ...
Stroke 40 (4), 1229-1236, 2009
Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction
B Levy, R Clere-Jehl, A Legras, T Morichau-Beauchant, M Leone, ...
Journal of the American College of Cardiology 72 (2), 173-182, 2018
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
CM Clase, JJ Carrero, DH Ellison, ME Grams, BR Hemmelgarn, ...
Kidney international 97 (1), 42-61, 2020
Heart failure drug treatment
P Rossignol, AF Hernandez, SD Solomon, F Zannad
The Lancet 393 (10175), 1034-1044, 2019
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ...
Science immunology 6 (62), eabl4348, 2021
Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study
A Benetos, C Labat, P Rossignol, R Fay, Y Rolland, F Valbusa, P Salvi, ...
JAMA internal medicine 175 (6), 989-995, 2015
Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone …
W Iraqi, P Rossignol, M Angioi, R Fay, J Nuée, JM Ketelslegers, J Vincent, ...
Circulation 119 (18), 2471-2479, 2009
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AA House, C Wanner, MJ Sarnak, IL Piña, CW McIntyre, P Komenda, ...
Kidney international 95 (6), 1304-1317, 2019
Evaluation of kidney function throughout the heart failure trajectory–a position statement from the Heart Failure Association of the European Society of Cardiology
W Mullens, K Damman, JM Testani, P Martens, C Mueller, J Lassus, ...
European journal of heart failure 22 (4), 584-603, 2020
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo …
R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo, S Warren, J Ma, ...
The Lancet 394 (10208), 1540-1550, 2019
Cardiorenal syndrome revisited
F Zannad, P Rossignol
Circulation 138 (9), 929-944, 2018
Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights …
N Lopez‐Andrès, P Rossignol, W Iraqi, R Fay, J Nuée, S Ghio, ...
European journal of heart failure 14 (1), 74-81, 2012
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20